Susan Geyer

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas”.

BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas

New England Journal of Medicine(2023)10.1056/nejmoa2213329

N/A

4.5DataRank · unranked

138 citations

Erin Twohy, Susan Geyer, Elizabeth R. Gerstner, Timothy J. Kaufmann, Shervin Tabrizi +23 more

Index60 Identifies Individuals at Appreciable Risk for Stage 3 Among an Autoantibody-Positive Population With Normal 2-Hour Glucose Levels: Implications for Current Staging Criteria of Type 1 Diabetes

Diabetes Care(2021)10.2337/dc21-0944

N/A

1.3DataRank · unranked

33 citations

María J. Redondo, Heba M. Ismail, Laura M. Jacobsen, Emily K. Sims, Jerry P. Palmer +5 more

Index60 as an additional diagnostic criterion for type 1 diabetes

Diabetologia(2021)10.1007/s00125-020-05365-4

N/A

0DataRank · unranked

27 citations

Brandon M. Nathan, Laura M. Jacobsen, Emily K. Sims, Laura E. Bocchino, Alberto Pugliese +8 more

Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.2000

N/A

0DataRank · unranked

20 citations

Erin Twohy, Susan Geyer, Elizabeth R. Gerstner, Timothy J. Kaufmann, Michael W. Ruff +15 more

Oral Glucose Tolerance Test Measures of First-phase Insulin Response and Their Predictive Ability for Type 1 Diabetes

The Journal of Clinical Endocrinology & Metabolism(2022)10.1210/clinem/dgac285

N/A

0DataRank · unranked

11 citations

Megan Warnock, Ping Xu, Susan Geyer, Jennifer B. Marks, Antoinette Moran +3 more

Index60 Is Superior to HbA1c for Identifying Individuals at High Risk for Type 1 Diabetes

The Journal of Clinical Endocrinology & Metabolism(2022)10.1210/clinem/dgac440

N/A

0DataRank · unranked

8 citations

Brian N. Bundy, Heba M. Ismail, Mark A. Clements, Megan Warnock, Susan Geyer +3 more

High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment

Diabetologia(2023)10.1007/s00125-023-06003-5

N/A

0DataRank · unranked

24 citations

Susan Geyer, S. Alice Long, Kevan C. Herold, Emily K. Sims

Systemic VSV-IFNβ-NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.7530

N/A

0DataRank · unranked

2 citations

Joselle Cook, Kah-Whye Peng, Susan Geyer, Brenda Ginos, Lianwen Zhang +7 more

Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study

The Oncologist(2020)10.1634/theoncologist.2020-0039

N/A

0DataRank · unranked

14 citations

Daniel G. Stover, Maryam B. Lustberg, Abigail B. Shoben, Meng Zhao, Ewa Mrózek +23 more

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood(2024)10.1182/blood.2024024756

N/A

0DataRank · unranked

50 citations

Rami S. Komrokji, Najla Al‐Ali, Alexandra Regelson, Susan Geyer, Anand Patel +39 more

Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals

Science Translational Medicine(2021)10.1126/scitranslmed.abc8980

N/A

0DataRank · unranked

361 citations

Brian N. Bundy, Kenneth Stier, Elisavet Serti, Noha Lim, S. Alice Long +18 more